Startseite>>Signaling Pathways>> Proteases>> Dipeptidyl Peptidase>>Saxagliptin (hydrochloride)

Saxagliptin (hydrochloride) (Synonyms: BMS-477118)

Katalog-Nr.GC44874

Saxagliptin (Hydrochlorid) (BMS-477118 Hydrochlorid) ist ein potenter, selektiver, reversibler, kompetitiver und oral aktiver Dipeptidylpeptidase-4 (DPP-4) (Ki \u003d 0,6-1,3 nM) Inhibitor.

Products are for research use only. Not for human use. We do not sell to patients.

Saxagliptin (hydrochloride) Chemische Struktur

Cas No.: 709031-78-7

Größe Preis Lagerbestand Menge
5mg
83,00 $
Auf Lager
10mg
143,00 $
Auf Lager
25mg
315,00 $
Auf Lager
50mg
546,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Saxagliptin is a potent inhibitor of dipeptidyl peptidase 4 (DPP-4; Ki = 0.6 nM). It inhibits DPP-4 ex vivo (ED50 = 0.12 μmol/kg) in plasma from normal fasted rats. Saxagliptin (0.3-3 mg/kg) reduces plasma glucose levels in Zuckerfa/fa diabetic rats in a dose-dependent manner. Oral administration at doses ranging from 1-10 μmol/kg increases plasma insulin levels and improves glucose clearance in ob/ob mice, a transgenic model of obesity. Saxagliptin induces systolic and diastolic dysfunction, reduces contractile force, and exacerbates ischemia-reperfusion injury-induced cardiac dysfunction in isolated guinea pig hearts. Formulations containing saxagliptin have been used for the treatment of type 2 diabetes.

Bewertungen

Review for Saxagliptin (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Saxagliptin (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.